Principal Financial Group Inc. purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,389,654 shares of the company's stock, valued at approximately $23,402,000. Principal Financial Group Inc. owned approximately 0.67% of Cellebrite DI as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. grew its holdings in Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock valued at $33,000 after buying an additional 1,017 shares during the last quarter. Pathway Financial Advisers LLC boosted its stake in shares of Cellebrite DI by 1,583.8% during the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock valued at $74,000 after acquiring an additional 4,118 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Cellebrite DI during the 2nd quarter worth about $71,000. nVerses Capital LLC acquired a new position in Cellebrite DI in the 2nd quarter valued at about $103,000. Finally, TD Asset Management Inc acquired a new position in Cellebrite DI in the 2nd quarter valued at about $121,000. Institutional investors and hedge funds own 45.88% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. Lake Street Capital lifted their price target on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. Craig Hallum increased their price target on Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Bank of America lifted their price objective on Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Finally, JPMorgan Chase & Co. increased their target price on Cellebrite DI from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $20.29.
Check Out Our Latest Stock Analysis on CLBT
Cellebrite DI Stock Up 0.8 %
Shares of CLBT stock traded up $0.14 during mid-day trading on Thursday, reaching $17.95. The company's stock had a trading volume of 720,061 shares, compared to its average volume of 1,157,215. The company's 50 day simple moving average is $17.70 and its 200-day simple moving average is $14.47. Cellebrite DI Ltd. has a 12-month low of $7.64 and a 12-month high of $21.00. The firm has a market capitalization of $3.70 billion, a PE ratio of -11.38, a price-to-earnings-growth ratio of 2.61 and a beta of 1.50.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. The business had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company's revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.09 earnings per share. As a group, research analysts anticipate that Cellebrite DI Ltd. will post 0.31 EPS for the current fiscal year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
